Financial Shenanigans

The Forensic Verdict

Convatec earns a 55 / 100 Elevated forensic risk score: reported cash generation is real, but presentation quality is stretched. The two highest-risk points are the 2025 free-cash-flow-to-equity redefinition, which lifted headline equity cash conversion to 101% while the prior definition was 61%, and the size of recurring adjusted-profit exclusions. The cleanest offset is that the 2025 audit opinion was unqualified, the Audit and Risk Committee reported no significant control failures, related-party disclosures are clean, and three-year cash flow still covers net income. The data point that would most change the grade is 2026 cash conversion after all capex: if receivables normalize and free cash flow remains strong after growth capex, the grade should fall; if the new cash metric stays strong only by excluding rising growth capex, the grade should rise.

Breeding Ground

Convatec has normal listed-company oversight, but incentives and metric design amplify the accounting-quality risk.

The breeding ground is mixed rather than hostile. The board had 9 directors with 7 independent directors, the Audit and Risk Committee chair has audit and CFO experience, the FY2025 audit opinion was unqualified, and non-audit fees were $0.6m versus $4.9m of audit fees. The weaker points are incentive design, Deloitte's long tenure before the EY transition for FY2026, and the old FCA action against former non-executive chair Christopher Gent for unlawfully disclosing inside information in 2018; the FCA said there was no evidence of trading or personal gain. That does not imply manipulation; it means the highest-risk accounting judgments sit close to the measures that determine pay and guidance credibility.

Earnings Quality

Earnings look directionally earned, but reported profit is no longer the number management asks investors to underwrite.

Receivables are the main income-statement cross-check. FY2025 revenue rose 6.6%, but receivables rose 25.1%; gross trade receivables rose to $384m from $311m, and receivables past due by more than 180 days rose to $33m from $16m. The allowance moved in the right direction, rising to $23m from $16m, but the pattern puts the burden on 2026 collections.

Gross margin is stable and not the issue. The issue is the widening distance between reported and adjusted operating profit: FY2025 reported operating margin fell to 13.0%, while adjusted operating margin rose to 22.3%. Management has a reasonable explanation for much of the gap, especially acquired-intangible amortization from the 2008 spin-out that should finish by mid-2026, but until that gap actually narrows the adjusted margin is a cleaner-looking version of the business than the income statement.

The 2025 InnovaMatrix impairment is the clearest big-bath test. The $72m charge followed the CMS payment-rate decision and left the InnovaMatrix platform intangible at $40m; the auditor identified the valuation as a new key audit matter and concluded management's judgments were reasonable. That makes the charge evidence of forecast risk and aggressive prior carrying value risk, not evidence of fraud.

Cash Flow Quality

Cash conversion is strong on the statutory cash-flow statement, but weaker under owner-earnings definitions that deduct all growth investment.

The multi-year cash test is the best offsetting evidence in the file. FY2023-FY2025 operating cash flow was $1.234B versus $496m of net income, and FCF after acquisitions was still $630m, or 1.27x net income. That coverage argues against a thesis that earnings are broadly fabricated, even though 2025 cash presentation deserves a haircut.

FY2025 working capital was not a simple cash-flow win. Receivables consumed $58m and inventory consumed $38m, while payables supplied $62m; trade payables separately rose to $217m from $125m. No supplier-finance programme was identified in the files reviewed, but the payable expansion is still a quality-of-cash item because it offset customer and inventory cash drag.

The redefinition is material. FY2025 free cash flow to equity was $362m under the new definition, but management disclosed $219m on the comparable prior definition; the earnings call stated prior-definition equity cash conversion was 61%, not 101%. A PM should underwrite the business on cash after all capex, then treat management's new FCFE as a capital-allocation KPI rather than owner earnings.

Metric Hygiene

Metric hygiene is the weakest part of the file because the highlighted metrics are moving away from reported profit and all-in free cash flow.

This is not a case where non-IFRS metrics are unreconciled. They are reconciled clearly. The forensic concern is that management's preferred numbers exclude items that are economically relevant to capital intensity, prior acquisitions, and the 2025 product impairment.

What to Underwrite Next

The next underwriting work should focus on whether 2025 was a temporary collection and capex transition year or a new pattern of metric engineering.

This forensic work should affect valuation and position sizing, not break the thesis by itself. Convatec's audit, controls, related-party disclosures, and multi-year cash conversion are too clean for a severe reliability discount, but the 2025 metric changes and working-capital pattern justify a required margin of safety until cash conversion after all capex and receivable collections are proven in the next annual report.